Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as solid tumors. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases.

Download DocumentationJuno Corporate Presentation - March 2017
Webcast ImageWebcast - Replay
Juno Therapeutics at Cowen and Company 37th Annual Health Care Conference
March 07, 2017 at 10:40 a.m. ET
Juno Therapeutics at Cowen and Company 37th Annual Health Care Conference
Tuesday, March 7, 2017 10:40 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Juno Therapeutics at 2017 Barclays Global Healthcare Conference
March 16, 2017 at 10:45 a.m. ET
Juno Therapeutics at 2017 Barclays Global Healthcare Conference
Thursday, March 16, 2017 10:45 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Webcast ImageWebcast - Replay
Q4 2016 Juno Therapeutics Earnings Conference Call
March 01, 2017 at 2:00 p.m. PT
Q4 2016 Juno Therapeutics Earnings Conference Call
Wednesday, March 1, 2017 2:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar

Recent News

DateTitle 
Mar. 01, 2017Juno Therapeutics Reports Fourth Quarter and 2016 Financial ResultsPrinter Friendly Version
Feb. 28, 2017Juno Therapeutics to Present at March 2017 Investor ConferencesPrinter Friendly Version
Feb. 22, 2017Juno Therapeutics to Report Full Year and Fourth Quarter 2016 Financial Results on Wednesday, March 1Printer Friendly Version
Jan. 27, 2017Juno Therapeutics Appoints Corsee D. Sanders as Executive Vice President and Head of Development OperationsPrinter Friendly Version

Upcoming Events

There are currently no events scheduled.

Past Events

DateTitle
03/16/17 10:45 a.m. ET
Juno Therapeutics at 2017 Barclays Global Healthcare Conference
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
JUNO (Common Stock)
ExchangeNASDAQ
Price$20.20
Change Stock is Down 0.08 (0.39%)
Volume1,243,527
Data as of Mar. 24, 2017 4:00 p.m. ET